The targeted inhibition of BCL‐2 for the treatment of AML has been linked to an increased risk of neutropenia, with a presumed mechanism of on‐target inhibition of BCL‐2 in neutrophil precursor cells [26]. Here, BCL2 is linked to neutropenia.